Holen Sie sich die Stockscreener-App
26.38
1.15%
0.30
Handel nachbörslich:
26.38
Schlusskurs vom Vortag:
$26.08
Offen:
$26.25
24-Stunden-Volumen:
530.70K
Relative Volume:
0.60
Marktkapitalisierung:
$1.56B
Einnahmen:
$13.05M
Nettoeinkommen (Verlust:
$-60.54M
KGV:
-22.74
EPS:
-1.16
Netto-Cashflow:
$-37.82M
1W Leistung:
+2.41%
1M Leistung:
+11.78%
6M Leistung:
-34.35%
1J Leistung:
-44.72%
1-Tages-Spanne:
$26.05
$26.60
1-Wochen-Bereich:
$25.81
$28.39
52-Wochen-Spanne:
$22.48
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Firmenname
Janux Therapeutics Inc
Sektor
Branche
Telefon
(858) 751-4493
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Vergleichen Sie JANX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
26.38 | 1.52B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-11 | Eingeleitet | Raymond James | Outperform |
| 2024-12-03 | Bestätigt | BTIG Research | Buy |
| 2024-12-03 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-03-21 | Eingeleitet | BTIG Research | Buy |
| 2024-03-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Eingeleitet | Wedbush | Outperform |
| 2022-11-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Is Janux Therapeutics Inc. a good long term investmentFree Stock Market Trend Analysis - jammulinksnews.com
What drives Janux Therapeutics Inc. stock priceUnrivaled growth potential - jammulinksnews.com
Janux Therapeutics Receives Buy Rating from Leerink Partners Amid Strategic Initiatives and Long-Term Growth Potential - AInvest
What analysts say about Janux Therapeutics Inc. stockAccelerated financial growth - jammulinksnews.com
Janux Therapeutics Inc. Stock Analysis and ForecastExceptional profit potential - Autocar Professional
Strategic Initiatives and Long-Term Potential Drive Buy Rating for Janux Therapeutics Inc. - TipRanks
Teacher Retirement System of Texas Sells 884 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Nisa Investment Advisors LLC - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Upgraded at Wall Street Zen - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $91.89 Consensus PT from Analysts - Defense World
E.W. Scripps (NASDAQ:SSP) Lowered to Sell Rating by Wall Street Zen - Defense World
Janux Therapeutics (JANX) Soars 2.31% on R&D Day Announcement - AInvest
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025 - BioSpace
Janux Therapeutics to Showcase New Preclinical Programs at Virtual R&D Day - AInvest
September 19th Options Now Available For Janux Therapeutics (JANX) - Nasdaq
How Janux Therapeutics Inc. stock performs during market volatilityExplosive Growth Potential - Newser
Why Janux Therapeutics Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
What makes Janux Therapeutics Inc. stock price move sharplyProfessional Stock Screener - Newser
Raymond James Financial Initiates Coverage on Janux Therapeutics (NASDAQ:JANX) - Defense World
Argus Initiates Coverage on CoreWeave (NASDAQ:CRWV) - Defense World
Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald - Defense World
Allspring Global Investments Holdings LLC Increases Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Raymond James initiates Janux Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Raymond James Initiates Janux Therapeutics at Outperform With $65 Price Target - MarketScreener
Janux Therapeutics initiated with an Outperform at Raymond James - TipRanks
Raymond James Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $65 - 富途牛牛
KBC Group NV Invests $66,000 in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
(JANX) On The My Stocks Page - news.stocktradersdaily.com
Janux Therapeutics Insiders Sell US$5.6m Of Stock, Possibly Signalling Caution - simplywall.st
Top Defense Stocks To Follow Now – July 1st - Defense World
2025's 10 Worst-Performing Stocks | Investing - US News Money
Janux Therapeutics: Riding Momentum into the Russell Indices and Beyond - AInvest
GAMMA Investing LLC Grows Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
When (JANX) Moves Investors should Listen - news.stocktradersdaily.com
JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target - MSN
Bank of America Securities Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
SG Americas Securities LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Janux Therapeutics Becomes Oversold (JANX) - Nasdaq
Closing Figures Unveiled: Janux Therapeutics Inc (JANX) Drop -5.18, Closes at 23.61 - DWinneX
Janux Therapeutics, Inc. (JANX) Stock Analysis: Biotechnology Pioneer with 256.30% Potential Upside - DirectorsTalk Interviews
Capstone Holding Corp. (NASDAQ:CAPS), Secures $1 Million Pangaea Stone Order in Expanding Territory - The Globe and Mail
Where are the Opportunities in (JANX) - news.stocktradersdaily.com
Janux Therapeutics reports annual meeting results By Investing.com - Investing.com South Africa
Janux Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Janux Therapeutics reports annual meeting results - Investing.com
Advanced Renal Cell Carcinoma Pipeline 2025: In-depth Clinical - openPR.com
Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):